Syva receives a positive opinion for Syvazul BTV 3 vaccine from the CVMP of the European Medicines Agency (EMA).
León – Parque Tecnológico – Spain, 22 januari 2025
On 15 January 2025, the Committee for Medicinal Products for Veterinary Use (CVMP) issued a positive opinion recommending the granting of a marketing authorisation for Syvazul BTV 3 vaccine. This step forward marks an important milestone in the fight against Bluetongue, and Syva is proud to be at the forefront of this innovation.
Protection against Bluetongue serotype 3
Syvazul BTV 3 contains inactivated Bluetongue virus serotype 3 (BTV-3/NET2023). The positive opinion of the CVMP concerns, for the time being, vaccination of sheep, for which a single dose of Syvazul BTV3 is required. Syva’s vaccine currently has a temporary authorization for use in bovine and ovine species in accordance with Article 110(2) of Regulation (EU) 2019/6. This vaccine represents an essential tool to protect flocks, especially in regions where Bluetongue serotype 3 virus has been identified as a major health threat.
History of Bluetongue serotype 3 (BTV-3) and Syva’s commitment
Bluetongue serotype 3 emerged in September 2023 in the Netherlands, severely affecting cattle and sheep herds in the region. From that moment on, Syva has led a rapid and effective response, working closely with the European veterinary authorities. Through Article 110(2) of Regulation (EU) 2019/6, temporary authorizations for use were achieved in 11 European countries and outside Europe to ensure early availability of the vaccine in areas of greatest need. These key steps have allowed for its progressive distribution while the data necessary for a full marketing authorization were being developed and reviewed. This approach has been key to mitigating the impact of the disease and protecting animal health at the European level.
Key benefits for farmers and animals
- Significant reduction of the impact of the disease: Syvazul BTV 3 reduces the harmful effects of Bluetongue, offering effective protection of the animals.
- Rapid onset of protection: Active immunity is achieved four weeks after completion of the primary vaccination schedule, allowing rapid protection of herds.
- Animal welfare benefits: Vaccination contributes to the reduction of suffering of affected animals, improving their quality of life.
- Economic sustainability for farmers: By reducing losses associated with the disease, Syvazul BTV 3 supports the profitability and economic stability of the sector.
- Importance of an optimal vaccination coverage: Ensuring high vaccination coverage in herds is essential to achieve mass immunity, reducing virus circulation and protecting both vaccinated and immunized animals. This strengthens the overall health of herds and minimizes the impact of future outbreaks.
Towards a promising future for animal health
Syva is fully committed to supporting veterinarians and farmers by offering innovative and reliable solutions. The adoption of a positive opinion by the CVMP for Syvazul BTV 3 is a decisive step towards a marketing authorisation and extended protection against the consequences of Bluetongue.
We will continue to collaborate with health authorities and industry stakeholders to ensure sufficient vaccine availability.
Downloads
You may also be interested in
30 January, 2025
Syvac® EH Marker, the first and only DIVA vaccine against EHD, is now authorized in Belgium
Syva is pleased to announce that the FAMHP/FAGG has granted emergency use authorization for its marker (DIVA) vaccine against EHD in accordance with Article 110(2) of Regulation (EU) 2019/6 for use in cattle and deer.
24 January, 2025
Call for the 28th edition of the Syva Award International for the best doctoral thesis in Animal Health
We are pleased to remind you that the call for applications for the 28th Syva Award International is open until 18 February 2025. We also remind you that for two years now, the Syva Award International is no longer limited to Spanish candidates, but invites all doctoral students of any nationality who have submitted their thesis in animal health...
11 December, 2024
César Carnicer is appointed vice-president of Veterindustria.
The Board of Directors of Veterindustria (Asociación Empresarial Española de la Industria de Sanidad y Nutrición Animal) has renewed yesterday, 10 December, the positions of president and vice-president of the employers' association. César Carnicer, director of Syva, takes over as vice-president of Veterindustria, while Diego García, senior vice-president of the Southern Europe Cluster at Zoetis, will be the new...
Media tool kit
We provide users, particularly journalists and the press, with a series of graphic documents, photographs and videos. We offer the free use of these documents under certain conditions
Journalist and Press Contact
Are you a journalist, part of the press or the media? Do you want to get information on our activities, validate your sources in a professional manner, obtain validated photographic material or request an interview?
Next Events
